Corrigendum to ‘Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up’: [ESMO Open 7(6):100602, December 2022] (ESMO Open (2022) 7(6), (S2059702922002320), (10.1016/j.esmoop.2022.100602))

The authors regret that there were errors in the text and published figures. The authors would like to apologise for any inconvenience caused. The corrections are as follows: On page 3, in Figure 1, an option is added after “cT1-T2, N0”: • High grade^cThis option then connects with the box containing “CT of the chest FDG–PET–CT [III, A]”. On page 3, in Figure 1 and the figure footnote, a new footnote ‘b’ is added to the following boxes: • cT3-T4, N0 or AdCC any stage^b• cT1-T2, N0^bb ^bFDG–PET–CT is recommended for treatment planning in lymph node-positive or high-grade SGC; otherwise, CT of the chest can suffice.On page 3, in Figure 1 and the figure footnote, a new footnote ‘c’ is added to the following box: • High grade^cc ^cDefinition of high-grade tumours is described in Section 1 of the Supplementary Material, available at https://doi.org/10.1016/j.esmoop.2022.100602. On page 3: • FDG–PET–CT is recommended in high-grade SGC for the detection of distant metastases [III, A].is replaced with: • FDG–PET–CT is recommended in high-grade or lymph-node positive SGC for the detection of distant metastases [III, A]. On page 5, in Figure 2: • No high-risk factors: RT to primary [IV, A]is replaced with: • High-risk factors: RT to primary [IV, A]On page 5, in Figure 2: • RT to neckis replaced with: • RT to level I-V for pN+ [IV, A]and an arrow is added between the box containing “END II-IV (I and V on indication) [IV, B] and the box containing “pN0”. On page 5, in Figure 2: • pN+ and no high-risk factors: RT to level I-V [IV, A]is replaced with an arrow to the box containing “RT to level I-V for pN+ [IV, A]”. On page 6, in Figure 3, an additional option is added following “Open approach [IV, A]” and “Selected transoral/endoscopic/robotic [V, A]”: • High-risk factors: RT to primary [IV, A] On page 8, in Figure 4, an additional option is added following “Resection of submandibular gland and level Ib [IV, B]”: • pN+with arrows connecting to “Comprehensive ND I-V including the primary [IV, A]” and “RT to level I-V [IV, A]”. On page 8, in Figure 4: • pN0: No additional treatmentis replaced with: • pN0with an arrow connecting to: • High-risk factors: RT to primary [IV, A] On page 9, before the recommendations of “Surgical management of the primary: submandibular gland cancer” the following text is added: • Surgical management of the primary: minor SGC and cancer of the sublingual gland o Depending on the anatomical site of origin, a classical open approach [IV, A] or endoscopic, transoral or combined transoral-endoscopic resection [V, A] are recommended in selected patients, with the aim of achieving free margins. On page 10: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (71% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.is replaced with: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (up to 60% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.